Portland, OR, May 20, 2020 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global anti-viral therapies market generated $38.31 billion in 2018, and is estimated to reach $46.21 billion by 2026, registering a CAGR of 2.4% from 2019 to 2026. The report offers an extensive analysis of changing market dynamics, value chain, business performance, supply chain, and competitive scenario.
Increase in viral infections and strong pipeline of anti-viral drugs across the globe drive the growth of the global anti-viral therapies market. However, high cost of anti-viral therapies may hinder the market growth. On the other hand, rise in number of product approvals for combination therapy create new opportunities in the coming years.
Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/6643
Covid-19 Scenario:
- The revenue generated from anti-viral therapies will not affected by coronavirus pandemic owing to the essential treatments to be given for conditions including HIV, hepatitis, herpes virus, and others.
- People have become more conscious about viral infections amid the coronavirus pandemic across the globe.
- Anti-viral therapies are also beneficial to control the spread of coronavirus as they include the treatments on the basic symptoms of Covid-19.
The report offers a detailed segmentation of the global anti-viral therapies market based on type, mechanism of action, application, and region.
Based on type, the branded drugs segment contributed to the largest share in 2018, accounting for more than half of the total share, and is estimated to maintain its dominant position during the forecast period. However, the generic drugs segment is expected to register the highest CAGR of 2.5% from 2019 to 2026.
Based on mechanism of action, the nucleotide polymerase inhibitor segment accounted for the largest share in 2018, holding nearly two-fifths of the total share, and is expected to maintain the largest share throughout the forecast period. However, the reverse transcriptase inhibitors segment is estimated to portray the highest CAGR of 3.1% during the forecast period.
Based on region, North America contributed the highest share, accounting for more than one-third of the total market share in 2018, and will maintain its dominance throughout the forecast period. However, Asia-Pacific is expected to grow at the highest CAGR of 2.8% from 2019 to 2026.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/6643
Leading market players analyzed in the research include F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott Laboratories, AstraZeneca plc, AbbVie Inc., Aurobindo Pharma Limited, Johnson & Johnson, and Merck & Co., Inc.
Avenue Basic Plan | Library Access | 1 Year Subscription |
Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.
Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter
Get more information: https://www.alliedmarketresearch.com/library-access
Similar Reports:
Cancer Immunotherapy Market - Global Opportunity Analysis and Industry Forecast, 2019-2026
Cancer Therapeutics Market - Global Opportunity Analysis and Industry Forecast, 2019-2026
Hadron Therapy Market - Global Opportunity Analysis and Industry Forecast, 2020-2027
Anti-Inflammatory Therapeutics Market - Global Opportunity Analysis and Industry Forecast, 2019-2026
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.